Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase

被引:39
|
作者
Cane, Patricia A. [1 ]
Green, Hannah
Fearnhill, Esther
Dunn, David
机构
[1] Hlth Protect Agcy, Ctr Infect, Salisbury SP4 0JG, Wilts, England
[2] MRC, Clin Trials Unit, London, England
基金
英国医学研究理事会;
关键词
accessory mutations; HIV drug resistance; reverse transcriptase inhibitors; viral fitness;
D O I
10.1097/QAD.0b013e3280129964
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To identify accessory mutations associated with high levels of resistance to reverse transcriptase inhibitors (RTI). Design: HIV pol sequences from routine resistance tests from over 3000 patients who were treatment experienced and infected with subtype B HIV-1 were analysed. Changes relative to the wild-type amino acid for codons 1-400 of reverse transcriptase were determined in two series: (i) samples showing the accumulation of thymidine analogue mutations (TAMs); and (ii) samples showing the accumulation of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations. Methods: Accessory mutations were identified as occurring in those codons in which there was a statistically significant association between the distribution of amino acids and the number of TAMs/NNRTI resistance mutations. Positions already established as drug resistance positions by the International AIDS Society - USA Panel were not included in this analysis. Results: Twenty-four positions were identified where accessory mutations were associated with the accumulation of TAMS (20, 35, 39, 43, 60, 83, 98, 101, 122, 135, 179, 196, 203, 208, 218, 223, 228, 284, 322, 356, 359, 360, 371 and 381). Likewise changes at 25 positions (6, 20, 35, 39, 43, 53, 68, 90, 98, 101, 122, 179, 200, 203, 208, 218, 221, 223, 228, 284, 318, 320, 348, 359 and 371) were associated with NNRTI mutations. The accumulation of accessory mutations correlated with increasing numbers of TAMS and NNRTI mutations. Conclusion: The development of high-level resistance to RTI is associated not only with the accumulation of recognized mutations but also with accessory mutations. (c) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:447 / 455
页数:9
相关论文
共 50 条
  • [21] Enhanced NRTI and NNRTI resistance is associated with mutations in the HIV-1 reverse transcriptase connection subdomain of subtype C patients
    Delviks-Frankenberry, K. A.
    Lengruber, R. B.
    Santos, A. F.
    Soares, M. A.
    Kearney, M.
    Maldarelli, F.
    Coffin, J. M.
    Pathak, V. K.
    ANTIVIRAL THERAPY, 2010, 15 : A78 - A78
  • [22] Involvement of novel HIV-1 reverse transcriptase mutations in the highly ordered regulation of NRTI resistance
    Ceccherini-Silberstein, F
    Svicher, V
    Sing, T
    Santoro, M
    Beerenwinkel, N
    Gago, F
    Bertoli, A
    Forbici, F
    Bellocchi, MC
    Narciso, P
    Monforte, AD
    Antinori, A
    Perno, CF
    ANTIVIRAL THERAPY, 2005, 10 : S106 - S106
  • [23] Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
    Mark J. Siedner
    Michelle A. Moorhouse
    Bryony Simmons
    Tulio de Oliveira
    Richard Lessells
    Jennifer Giandhari
    Stephen A. Kemp
    Benjamin Chimukangara
    Godspower Akpomiemie
    Celicia M. Serenata
    Willem D. F. Venter
    Andrew Hill
    Ravindra K. Gupta
    Nature Communications, 11
  • [24] Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART
    Nouchi, A.
    Nguyen, T.
    Valantin, M. A.
    Simon, A.
    Sayon, S.
    Agher, R.
    Calvez, V.
    Katlama, C.
    Marcelin, A. G.
    Soulie, C.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (08) : 2141 - 2146
  • [25] Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy
    Santoro, Maria Mercedes
    Svicher, Valentina
    Gori, Caterina
    Zaccarelli, Mauro
    Tozzi, Valerio
    Forbici, Federica
    d'Arrigo, Roberta
    Trotta, Maria Paola
    Bellocchi, Maria Concetta
    Visco-Comandini, Ubaldo
    Cenci, Alessandra
    Bertoli, Ada
    Narciso, Pasquale
    Antinori, Andrea
    Perno, Carlo Federico
    Ceccherini-Silberstein, Francesca
    NEW MICROBIOLOGICA, 2006, 29 (02): : 89 - 100
  • [26] Molecular modeling, studies of drug resistance conferred by mutations in HIV-1 reverse transcriptase.
    Chong, YH
    Shim, JY
    Schinazi, RF
    Chu, CK
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U668 - U668
  • [27] Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1
    Turner, D
    Brenner, B
    Wainberg, MA
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (01) : 53 - 57
  • [28] Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
    Siedner, Mark J.
    Moorhouse, Michelle A.
    Simmons, Bryony
    de Oliveira, Tulio
    Lessells, Richard
    Giandhari, Jennifer
    Kemp, Stephen A.
    Chimukangara, Benjamin
    Akpomiemie, Godspower
    Serenata, Celicia M.
    Venter, Willem D. F.
    Hill, Andrew
    Gupta, Ravindra K.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [29] Involvement of novel HIV-1 reverse transcriptase mutations in the highly ordered regulation of NRTI resistance
    Ceccherini-Silberstein, F
    Svicher, V
    Sing, T
    Santoro, M
    Beerenwinkel, N
    Gago, F
    Bertoli, A
    Forbici, F
    Bellocchi, MC
    Narciso, P
    d'Arminio Monforte, A
    Antinori, A
    Perno, CF
    ANTIVIRAL THERAPY, 2005, 10 (04) : S106 - S106
  • [30] Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors
    Harrigan, PR
    Mo, T
    Wynhoven, B
    Hirsch, J
    Brumme, Z
    McKenna, P
    Pattery, T
    Vingerhoets, J
    Bacheler, LT
    AIDS, 2005, 19 (06) : 549 - 554